Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
Part of paid clinical trials in Baltimore, Maryland.
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study ID
- NCT02864316
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Solid Tumors Induced by Prior Radiation Exposure
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — DRUG
Study Details
The purpose of this study is to determine whether Nivolumab is effective in the treatment of radiation-induced solid tumors.
Key Dates
- Start date
- Dec 31, 2016
- Status verified
- Aug 2019
- Primary completion
- Aug 31, 2018
- Completion
- Sep 30, 2018
Study Design
- Enrollment
- 6 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Radiation-Induced Metastatic Sarcomaa flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
- Experimental: Radiation-Induced Non-Sarcoma Metastatic Solid Tumorsa flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
Primary Outcome Measure
Best Objective Response Rate [ Time Frame: Up to 24 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Sidney Kimmel Cancer Center @ Johns Hopkins | Baltimore | Maryland | 21231 | - |
Find similar trials in Baltimore, MD
By research site